Using AI to create personalized treatments for Alzheimer's Disease
SmartAD for Intelligent Alzheimer’s Disease(AD) Personalized Combination Therapy
This study is working on a smart app that will help doctors create personalized treatment plans for people with Alzheimer's Disease who also have other health issues like heart problems, diabetes, or depression, by looking at how different medications affect their thinking skills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10701069 on NIH RePORTER |
What this research studies
This research aims to develop an artificial intelligence application called SmartAD that will help evaluate cognitive functions and create personalized treatment plans for Alzheimer's Disease (AD) patients who also have common comorbidities like cardiovascular diseases, diabetes, and depression. By analyzing clinical data from the University of Pittsburgh Alzheimer’s Disease Research Center, the project seeks to understand how different medications for these comorbidities can impact cognitive functions in AD patients. The goal is to improve treatment outcomes by tailoring therapies based on individual patient profiles and their specific health conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are Alzheimer's Disease patients who also have comorbid conditions such as cardiovascular diseases, diabetes, or depression.
Not a fit: Patients with Alzheimer's Disease who do not have any comorbidities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for Alzheimer's Disease patients, potentially improving their cognitive function and quality of life.
How similar studies have performed: While the use of AI in healthcare is gaining traction, this specific approach to combining comorbidity medications for Alzheimer's Disease is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Xie, Xiang-Qun — University of Pittsburgh at Pittsburgh
- Study coordinator: Xie, Xiang-Qun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.